pyrimidine has been researched along with Triple Negative Breast Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, H; Jeong, JY; Jo, J; Jung, YS; Kim, H; Kim, S; Oh, JY; Park, YH; Yun, H | 1 |
| Jiang, Y; Ouyang, L; Sun, D; Wang, J; Yang, S; Yao, D; Yu, Y; Zhang, J; Zhao, Y; Zhou, Y; Zhu, L | 1 |
| Asara, JM; Brown, KK; Spinelli, JB; Toker, A | 1 |
3 other study(ies) available for pyrimidine and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
SAR optimization studies on a novel series of 2-anilinopyrimidines as selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
Topics: Cell Line, Tumor; Female; Humans; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2019 |
Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2017 |
Adaptive Reprogramming of
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cellular Reprogramming; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Isoxazoles; Leflunomide; Mice; Pyrimidines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |